Compare Vanguard Growth Index Fund ETF (VUG) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Growth Index Fund ETF vs GeneDx Holdings Corp — how do they compare? Vanguard Growth Index Fund ETF trades at $87.59, while GeneDx Holdings Corp trades at $86.53 (market cap $2.58B). The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| VUG | WGS | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $90.29 | $167.51 |
52-Week Low | $70.00 | $34.51 |
Market Cap | — | $2.58B |
Enterprise Value | — | $2.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vanguard Growth ETF (VUG) trades at $88.12, down 0.37% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF shows strong institutional buying interest, with multiple advisors increasing positions in Q2 2026, as reported by SEC filings. Recent news highlights performance comparisons with value-oriented peers and emphasizes its low-cost, large-cap growth focus.
The outlook for VUG remains positive given its exposure to growth stocks and institutional accumulation, though risks include market rotation away from growth and concentration in large-cap names. Investors should weigh its low expense ratio and growth potential against broader market volatility and sector-specific headwinds.
WGS trades at $85.87, down 0.14% on the day, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4 million, beating estimates, and achieved adjusted profitability ahead of schedule. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics, driving positive sentiment.
Outlook is cautiously optimistic due to strong analyst support (90.9% buy ratings) and revenue growth, but risks include negative net income margins, high valuation multiples, and ongoing class action lawsuits. The stock's upside potential hinges on sustained operational improvements and market expansion in genomics diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
